Hypoxia Pathway Activation Restricts Measles and Nipah Viruses

Study Background and Research Question

Paramyxoviridae viruses, including measles virus (MeV) and Nipah virus (NiV), are responsible for severe human diseases with significant morbidity and mortality worldwide. While vaccination campaigns have reduced the global burden of MeV, outbreaks still occur and can lead to devastating neurological complications in vulnerable populations. NiV, with its high fatality rates and epidemic potential, remains a critical public health concern due to the absence of approved antiviral therapies or vaccines for human use. Identifying host factors and cellular pathways that can be manipulated to inhibit viral replication is an urgent research priority. The central question addressed by Canus et al. (Emerging Microbes & Infections, 2025) is whether pharmacological activation of the hypoxia response pathway can restrict infections by MeV and NiV in relevant cellular and tissue models.

Key Innovation from the Reference Study

The primary innovation in this research lies in demonstrating that pharmacological stabilization of hypoxia-inducible factors (HIFs)—via inhibition of prolyl-hydroxylase domain (PHD) enzymes—can potently suppress MeV and NiV replication. Unlike conventional antiviral approaches that directly target viral proteins, this strategy leverages a host-directed mechanism: the induction of cellular hypoxia response pathways. The study systematically validates this approach using chemically distinct PHD inhibitors, highlighting the generalizability and robustness of HIF-pathway activation as an antiviral strategy. Notably, the antiviral effects were demonstrated both in vitro and ex vivo, strengthening the translational relevance of the findings (reference study).

Methods and Experimental Design Insights

The investigators employed a workflow beginning with a library-based screen of metabolic pathway modulators to identify compounds that restrict MeV infection in cultured cells. Molidustat, a clinically relevant PHD inhibitor, emerged as a lead compound. The study then expanded to ex vivo organotypic cultures of hamster cerebellum and lung—models that more closely recapitulate the in vivo tissue environment for both MeV and NiV infections.

Pharmacological induction of the hypoxia response was confirmed by transcriptomic analysis, ensuring that observed antiviral effects correlated specifically with HIF pathway activation. Two additional PHD inhibitors, Roxadustat and Daprodustat, chemically unrelated to Molidustat, were tested to assess class effects. Viral infection levels were quantified using immunostaining and RNA readouts, and the requirement for HIF dependency was validated using genetic and pharmacological controls.

Protocol Parameters

• Compound Pretreatment: Cells or organotypic tissues were pretreated with PHD inhibitors (e.g., Molidustat) for 16–24 hours prior to viral challenge to ensure HIF stabilization.
• Compound Concentration: Molidustat was applied at concentrations ranging from 10–50 μM, with dosing confirmed by viability and target engagement assays.
• Ex Vivo Culture: Organotypic cerebellum and lung slices from hamsters were maintained under air-liquid interface conditions and exposed to inhibitors before and during viral infection.
• Transcriptomic Validation: Gene expression analysis of HIF target genes (e.g., VEGFA, GLUT1) was performed to confirm pathway activation.
• Quantification of Infection: Viral burden was measured by immunofluorescence staining for viral proteins and by RT-qPCR for viral RNA.

Core Findings and Why They Matter

Key findings from the study include:

• PHD inhibition by Molidustat significantly reduced MeV infection in vitro, with effects dependent on HIF stabilization and not attributable to cytotoxicity.
• In ex vivo cerebellum cultures, Molidustat induced robust hypoxia response gene expression and limited MeV replication. Similar results were obtained with Roxadustat and Daprodustat, indicating a class effect of PHD inhibitors.
• Molidustat also suppressed NiV infection in organotypic cerebellum and lung slices, the primary target tissues in disease, suggesting that the antiviral mechanism is effective against multiple paramyxoviruses.
• Transcriptomic profiling confirmed activation of the canonical HIF pathway, supporting the mechanistic link between HIF stabilization and antiviral activity.

These results collectively provide compelling evidence that pharmacological activation of the hypoxia response pathway represents a promising host-directed antiviral approach, with potential to be rapidly repurposed given the clinical availability of PHD inhibitors.

Comparison with Existing Internal Articles

Several internal resources corroborate and complement the findings of Canus et al. For instance, previous coverage of this study emphasized the potential of HIF pathway induction as a broad-spectrum antiviral strategy, highlighting its translational implications. In addition, methodological guides such as DiscoveryProbe Metabolism-related Compound Library: Advanced Assay Solutions and DiscoveryProbe™ Metabolism-related Compound Library: Prec... discuss the utility of curated metabolism-related compound libraries in dissecting host metabolic pathways, supporting the approach of screening for host-targeted antiviral candidates.

These internal articles underscore the role of metabolism research compound collections in enabling high-throughput metabolic enzyme inhibition assays and the modulation of cellular pathways such as PPAR receptor and HMG-CoA reductase activity. The workflow strategies described therein are directly applicable to studies aiming to identify host factors in viral infection, as exemplified by the reference study.

Limitations and Transferability

While the study provides strong in vitro and ex vivo evidence for the antiviral efficacy of PHD inhibitors, several limitations warrant consideration. First, the translation from ex vivo organotypic cultures to in vivo efficacy and safety in animal models or humans remains to be demonstrated. Second, the induction of a hypoxia-like state could have pleiotropic effects on tissue physiology, potentially complicating therapeutic application. Finally, the precise molecular mechanisms by which HIF stabilization impairs paramyxovirus replication require further elucidation.

Importantly, the study’s approach is transferable to other RNA viruses and host-pathway targets, provided that suitable experimental models and pathway modulators are available. However, clinical application will require careful assessment of toxicity, tissue specificity, and potential off-target effects of chronic HIF pathway induction.

Why this cross-domain matters, maturity, and limitations

This research bridges the domains of metabolic pathway modulation and antiviral therapy by demonstrating that compounds traditionally used for anemia or ischemia (e.g., PHD inhibitors) can be repurposed for infectious disease applications. The maturity of the evidence is robust at the preclinical level, with both cell-based and organotypic tissue data, but further work is needed for clinical translation. The cross-domain approach highlights the utility of metabolism-related compound libraries for antiviral drug discovery, but also underscores the need for context-specific validation to address potential limitations in safety and efficacy.

Research Support Resources

For researchers seeking to emulate or extend these workflows, curated compound collections such as the DiscoveryProbe™ Metabolism-related Compound Library (SKU L1032) offer a practical solution. Comprising 493 cell-permeable metabolism modulators, this library enables systematic screening of metabolic pathways—including PHD, PPAR, and HMG-CoA reductase targets—in both in vitro and ex vivo models. Supplied as 10 mM DMSO solutions for high-throughput compatibility, the library supports applications in metabolic enzyme inhibition assays, pathway elucidation, and host-targeted antiviral research. As highlighted in both the reference study and related workflow articles, such resources can accelerate the identification and mechanistic validation of host-directed antiviral strategies.